Tech Company Financing Transactions

HemaQuest Pharmaceuticals Funding Round

On 11/2/2007, HemaQuest Pharmaceuticals raised $20 million in Series A financing from De Novo Ventures, Forward Ventures and Lilly Ventures.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series A
Proceeds Purpose
HemaQuest will use the funds primarily to support the clinical development of its lead drug candidate, an orally administered agent for treating sickle cell anemia and beta thalassemia.

Company Information

Company Status
Out of Business
Mailing Address
11995 El Camino Real 302
San Diego, CA 92130
Email Address
HemaQuest is a company developing proprietary small molecule therapeutics to treat serious blood disorders.
HemaQuest Pharmaceuticals LinkedIn Company Profile
Social Media
HemaQuest Pharmaceuticals Company Twitter Account
Company News
HemaQuest Pharmaceuticals News
HemaQuest Pharmaceuticals on Facebook
HemaQuest Pharmaceuticals on YouTube

Management Team

Email & Social
Chief Executive Officer
John Longenecker
  John Longenecker LinkedIn Profile  John Longenecker Twitter Account  John Longenecker News  John Longenecker on Facebook
Chief Financial Officer
Tamara Seymour
  Tamara Seymour LinkedIn Profile  Tamara Seymour Twitter Account  Tamara Seymour News  Tamara Seymour on Facebook
Chief Medical Officer
Richard Ghalie
  Richard Ghalie LinkedIn Profile  Richard Ghalie Twitter Account  Richard Ghalie News  Richard Ghalie on Facebook



Browse more venture capital transactions:

Prev: 11/2/2007: Corthera venture capital transaction
Next: 11/2/2007: MedAssets venture capital transaction


Share this article


Where The Data Comes From

We do our best to document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary